



INTRAVENOUS INFUSIONS PLC

MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

Intravenous Infusions PLC
Unaudited Financial Statements for the
Year Ended December 2024



INTRAVENOUS INFUSIONS PLC
 MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

KEY FINANCIAL HIGHLIGHTS

	31 DEC 2024 UNAUDITED GH¢	31 DEC 2023 UNAUDITED GH¢	% CHANGE YOY
Revenue	25,124,936	31,391,463	-20%
Gross Profit	12,392,880	18,057,379	-31%
Finance Costs	138,284	330,197	-58%
Operating Profit	692,178	7,052,994	-90%
Net Profit/(Loss) before tax	(84,008)	6,228,922	-101%
Net Shareholders' funds	17,538,105	22,058,357	-20%
Cash and cash Equivalent	1,513,066	499,518	203%
Trade and other receivables	11,314,227	16,425,816	-31%

UNAUDITED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	31 DEC 2024 UNAUDITED GH¢	31 DEC 2023 UNAUDITED GH¢	% CHANGE YOY
Revenue	25,124,936	31,391,463	-20%
Cost of operations	(12,732,057)	(13,057,379)	-2%
Gross profit	12,392,880	18,334,084	-32%
Other income	9,932	21,205	-53%
Operating and other expenses	(11,710,634)	(11,302,295)	4%
Profit before finance cost and tax	692,178	7,052,994	-90%
Finance cost	(138,284)	(330,197)	-58%
Depreciation and Amortization	(637,902)	(493,875)	29%
Profit before tax	(84,008)	6,228,922	-101%
Income tax expense	0.00	(1,167,923)	0%
Profit for the period	(84,008)	(5,060,999)	-102%
Earnings per share	-0.0003	0.018	-102%



INTRAVENOUS INFUSIONS PLC
 MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

UNAUDITED STATEMENT OF FINANCIAL POSITION

	31-Dec-24	31-Dec-23	% CHANGE
	UNAUDITED	UNAUDITED	YOY
	GH¢	GH¢	
ASSETS			
Non-current assets			
Property, plant and equipment	28,149,636	23,862,409	18%
Current assets			
Inventory	6,086,442	6,060,034	0%
Trade and other receivables	11,314,227	16,425,816	-31%
Cash	1,513,066	499,518	203%
Total current assets	18,913,736	22,985,368	-18%
Total assets	47,063,372	46,847,777	0%
Equity			
Stated capital	11,626,451	11,626,451	0%
Retained earnings	6,758,607	6,842,615	-1%
Capital surplus	2,103,120	2,103,120	0%
Total equity	20,488,178	20,572,187	0%
Non-Current Liability			
Deferred Tax liability	393,673	252,317	56%
Medium term loan	8,335,178	11,938,654	-30%
Total Non- current liability	8,728,851	12,225,250	-29%
Current liabilities			
Borrowings	874,283	1,293,379	-32%
Trade and other payables	16,972,060	12,756,961	33%
Current tax	-	-	0%
Employee Benefit obligation	-	-	0%
Total Current Liabilities	17,846,343	14,050,340	27%
Total Liabilities	26,575,194	26,275,589	1%
Total Liabilities and Equity	47,063,371	46,847,777	0%



INTRAVENOUS INFUSIONS PLC
 MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
"Saving lives since 1969"

UNAUDITED STATEMENT OF CHANGES IN EQUITY

	Stated capital	Deposit for shares	Income surplus	Capital surplus	Total
Balance at 1 st Jan 2024	11,626,451		6,842,615	2,103,120	20,572,186
issue of shares(net) Profit/(Loss) for the period Dividend paid Transfer from profit and loss			(84,008)		(84,008)
At 31 th December 2024	11,626,451	0	6,758,607	2,103,120	20,488,178

UNAUDITED STATEMENT OF CASH FLOWS

	31-Dec-24 UNAUDITED GH¢	31-Dec-23 UNAUDITED GH¢
Operating activities		
Profit before tax	(84,008)	6,228,922
Adjustments for non-cash income and expenses:		
Net employee obligation		
Depreciation of property, plant and equipment	637,902	493,875
Cash flow included in operating activities	553,894	6,722,797
Changes in operating assets and liabilities		
Decrease/increase in trade and other receivables	5,283,091	196,010
Increase/decrease in trade payables	1,292,442	(2,918,728)
Increase/decrease in inventory	178,446	566,816
Cash flow from operating activities	7,305,872	4,566,895
Tax paid	-	
Dividend paid	-	
Net cash from operating activities	7,305,872	4,566,895
Cash flows from investing activities		
Purchases of equipment	(2,198,800)	1,595,180
Net cash used in investing activities	(2,198,800)	1,595,180



INTRAVENOUS INFUSIONS PLC
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS
Saving lives since 1969

Cash flows from financing activities		
Dividend paid	-	
Increase in borrowings	(3,887,639)	(6,469,268)
Net cash used in financing activities	(3,887,639)	(6,469,268)
Net (increase/decrease) in cash and cash equivalents	1,219,433	(307,193)
Cash and cash equivalents at beginning of year	293,633	806,710
Cash and cash equivalents at 31 Dec 2024	1,513,066	499,517

Moukhtar Soalih
(Managing Director)

Eugenia Bulley
(General Manager, Finance and Administration)